What is HC Wainwright’s Forecast for DRTS FY2025 Earnings?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Analysts at HC Wainwright cut their FY2025 EPS estimates for shares of Alpha Tau Medical in a research report issued on Monday, November 24th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.51) for the year, down from their previous forecast of ($0.48). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s FY2026 earnings at ($0.49) EPS.

A number of other equities research analysts have also recently commented on the stock. Wall Street Zen upgraded shares of Alpha Tau Medical to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alpha Tau Medical has a consensus rating of “Hold” and a consensus price target of $9.00.

Alpha Tau Medical Price Performance

Shares of Alpha Tau Medical stock opened at $3.74 on Wednesday. The firm has a market cap of $317.23 million, a PE ratio of -7.19 and a beta of 1.06. Alpha Tau Medical has a twelve month low of $2.30 and a twelve month high of $4.69. The business has a 50-day moving average price of $4.00 and a 200 day moving average price of $3.46. The company has a quick ratio of 5.81, a current ratio of 8.43 and a debt-to-equity ratio of 0.08.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Thursday, November 20th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02).

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in shares of Alpha Tau Medical during the 1st quarter worth $53,000. Envestnet Asset Management Inc. purchased a new stake in Alpha Tau Medical during the third quarter worth about $62,000. Bank of America Corp DE boosted its holdings in Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares in the last quarter. Millennium Management LLC acquired a new position in Alpha Tau Medical during the third quarter worth about $170,000. Finally, Mariner LLC increased its holdings in Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after buying an additional 80,129 shares in the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.